PATENT CLAIM ANALYSIS

Application Number: 15961681
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-01
Patent Classification: ["514", "007200"]

Abstract:
The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.

Claim (Index 3):
The method of  claim 1 , wherein the patient has not previously received glucose-lowering therapy.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 1.59375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13467757', '15237285', '13467707', '14781857', '15073364']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.656956191820372
- 35 USC 102 Novelty (BERT): 0.5511365471175798
- Combined Prediction Score: 0.6463742273500929
- Mean Citation Score: 364.889454
- Max Citation Score: 420.30463
- Similarity Product: 291.21893286494253

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test